Sector News

Daiichi Sankyo to shut down German antibody unit U3

December 8, 2015
Life sciences

Daiichi Sankyo has said it will close down its German antibody subsidiary U3 Pharma and transfer its operations to a research unit in Japan.

The company said the move is part of an initiative to “strengthen its global R&D capabilities by increasing efficiency and streamlining processes”.

Martinsried-based U3 Pharma – which was acquired by Daiichi Sankyo in a €150m deal in 2008 – employs around 40 members of staff and specialises in the development of antibody treatments for cancer.

U3 Pharma’s lead candidate patritumab (U3-1287), an anti-HER3 antibody in clinical trials for non-small cell lung cancer (NSCLC), breast cancer and head and neck cancer, was highlighted by Daiichi Sankyo as a key driver for U3’s acquisition.

Seven years on, it remains the only candidate from U3 in clinical development, with all other projects listed in the German company’s latest update still in early-stage or preclinical testing.

The announcement comes shortly after Daiichi Sankyo announced major job cuts in the US – mainly in its salesforce – along with a revamp of its R&D operations with the creation of a research alliance with fellow Japanese drugmaker Astellas and the launch of its TaNeDS open innovation drive in Europe.

The restricting comes as Daiichi Sankyo faces the loss of patent protection in the US for Benicar (olmesartan), a $2.4bn-a-year product used to treat high blood pressure.
US sales of the drug are around $900m a year and the Japanese company is already coping with generic competition to the cholesterol drug Welchol (colesevelam), which at its peak had US sales of around $300m a year.

Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) – as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for fibromyalgia – to help it cope with the anticipated loss of revenues resulting from the patent losses.

By Phil Taylor

Source: PM Live

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend